Venner, Christopher P <br/><br/>
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.  [electronic resource] 

 -  Blood  May 2012 
 - 4387-90 p.  digital 
<br/><br/> Publication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2011-10-388462  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Amyloid--metabolism<br/>Amyloidosis--drug therapy<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Clonal Evolution--drug effects<br/>Cohort Studies<br/>Cyclophosphamide--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Pyrazines--administration & dosage<br/>Recurrence<br/>Retrospective Studies<br/>Treatment Outcome